GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » InnovAge Holding Corp (NAS:INNV) » Definitions » Sloan Ratio %

InnovAge Holding (InnovAge Holding) Sloan Ratio % : 5.18% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is InnovAge Holding Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

InnovAge Holding's Sloan Ratio for the quarter that ended in Mar. 2024 was 5.18%.

As of Mar. 2024, InnovAge Holding has a Sloan Ratio of 5.18%, indicating the company is in the safe zone and there is no funny business with accruals.


InnovAge Holding Sloan Ratio % Historical Data

The historical data trend for InnovAge Holding's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnovAge Holding Sloan Ratio % Chart

InnovAge Holding Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Sloan Ratio %
12.71 -1.43 -3.18 1.15 1.52

InnovAge Holding Quarterly Data
Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 1.52 9.71 0.87 5.18

Competitive Comparison of InnovAge Holding's Sloan Ratio %

For the Medical Care Facilities subindustry, InnovAge Holding's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnovAge Holding's Sloan Ratio % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, InnovAge Holding's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where InnovAge Holding's Sloan Ratio % falls into.



InnovAge Holding Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

InnovAge Holding's Sloan Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Sloan Ratio=(Net Income (A: Jun. 2023 )-Cash Flow from Operations (A: Jun. 2023 )
-Cash Flow from Investing (A: Jun. 2023 ))/Total Assets (A: Jun. 2023 )
=(-40.673-20.236
--69.521)/567.358
=1.52%

InnovAge Holding's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(-30.815--25.62
--32.499)/527.355
=5.18%

InnovAge Holding's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -11.177 (Jun. 2023 ) + -10.304 (Sep. 2023 ) + -3.447 (Dec. 2023 ) + -5.887 (Mar. 2024 ) = $-30.8 Mil.
InnovAge Holding's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was 13.151 (Jun. 2023 ) + -32.985 (Sep. 2023 ) + -9.294 (Dec. 2023 ) + 3.508 (Mar. 2024 ) = $-25.6 Mil.
InnovAge Holding's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -5.192 (Jun. 2023 ) + -3.141 (Sep. 2023 ) + -23.111 (Dec. 2023 ) + -1.055 (Mar. 2024 ) = $-32.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnovAge Holding  (NAS:INNV) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, InnovAge Holding has a Sloan Ratio of 5.18%, indicating the company is in the safe zone and there is no funny business with accruals.


InnovAge Holding Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of InnovAge Holding's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


InnovAge Holding (InnovAge Holding) Business Description

Traded in Other Exchanges
N/A
Address
8950 East Lowry Boulevard, Denver, CO, USA, 80230
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.
Executives
Teresa Sparks director 40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Nicole Damato officer: CHIEF LEGAL OFFICER 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Benjamin C Adams officer: CHIEF FINANCIAL OFFICER 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Patricia Fontneau director 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Christine Bent officer: CHIEF OPERATIONS OFFICER 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Thomas Scully director 320 PARK AVENUE, SUITE # 2500, NEW YORK NM 10022
Richard Feifer officer: CHIEF MEDICAL OFFICER C/O GENESIS HEALTHCARE, INC., 101 EAST STATE STREET, KENNETT SQUARE PA 19348
James G Carlson director 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Patrick T Blair officer: PRESIDENT 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Caroline Dechert director 580 CALIFORNIA ST., SUITE 1700, SAN FRANCISCO CA 94104
Pavithra Mahesh director 601 LEXINGTON AVE., 53RD FLOOR, NEW YORK NY 10022
Maureen Hewitt director, officer: CEO, President and Director 8950 E. LOWRY BLVD., DENVER CO 80230
Maria Lozzano officer: CORPORATE COO 8950 E. LOWRY BLVD., DENVER CO 80230
Robin Doerr officer: CHIEF SALES AND MKTG. OFFICER 8950 E. LOWRY BLVD., DENVER CO 80230
Melissa Welch officer: CHIEF MEDICAL OFFICER 8950 E. LOWRY BLVD., DENVER CO 80230